Dani Bach, an investment professional, has joined the board of Crescendo Biologics Ltd as a non-executive director, replacing Rob Woodman. Dr Bach represents IP Group Plc on the board, which is one of Crescendo’s largest shareholders.
Crescendo is developing multifunctional biologics for the treatment of cancer.
Dr Bach holds a PhD in molecular biology from the University of Barcelona and a MBA from the Escuela de Organización Industrial in Madrid, both in Spain. He has extensive investment experience in areas ranging from medical devices to protein therapeutics and is currently partner for life sciences at IP Group.
Crescendo announced the appointment on 21 March 2018.
Copyright 2018 Evernow Publishing Ltd